抗警报素生物制剂:靶向上皮细胞治疗哮喘
重症哮喘生物制剂仅减少约50%急性发作,且对2型低哮喘无效。上皮来源的警报素TSLP、IL-33和IL-25位于2型炎症上游,靶向这些警报素可能为2型高和2型低哮喘提供新治疗选择。本文综述警报素的作用及抗警报素生物制剂的潜在角色,并讨论可能获益患者的临床表型和生物标志物。
要点
- 现有生物制剂仅减少约50%急性发作,2型低哮喘无有效治疗。
- 警报素TSLP、IL-33、IL-25位于2型炎症上游,是潜在治疗靶点。
- 抗警报素可能对2型高和2型低哮喘均有效,生物标志物可助筛选应答者。
核心结论
- 靶向上皮警报素(TSLP、IL-33、IL-25)可能克服现有生物制剂仅部分减少急性发作的局限。
- 抗警报素治疗可能对2型高和2型低哮喘均有效,并改善肺功能。
- 生物标志物可能有助于识别抗警报素治疗的潜在应答者。
研究设计与样本
- 综述文章,讨论警报素在哮喘中的作用及抗警报素生物制剂的潜在角色。
主要发现
- 现有生物制剂(抗IgE、抗IL-5、抗IL-5Rα、抗IL-4Rα)在研究中减少急性发作约50%。
- 抗IL-5治疗降低嗜酸性粒细胞时FeNO可不变,抗IL-4Rα治疗降低FeNO时嗜酸性粒细胞可不变。
- 警报素TSLP、IL-33、IL-25由气道上皮释放,启动涉及IL-4、IL-5、IL-13的广泛炎症反应。
- 该炎症反应最终导致急性发作的典型特征:嗜酸性炎症、黏液产生和支气管痉挛。
临床怎么用
- 抗警报素为重症哮喘提供新治疗方向,尤其2型低哮喘。
- 临床可结合生物标志物筛选可能从抗警报素治疗中获益的患者。
局限性
- 本文为综述,未报告原始研究数据。
- 抗警报素生物制剂的疗效和安全性需临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal antibody therapies have significantly improved treatment outcomes for patients with severe asthma; however, a significant disease burden remains. Available biologic treatments, including anti-immunoglobulin (Ig)E, anti-interleukin (IL)-5, anti-IL-5Rα and anti-IL-4Rα, reduce exacerbation rates in study populations by approximately 50% only. Furthermore, there are currently no effective treatments for patients with severe, type 2-low asthma. Existing biologics target immunological pathways that are downstream in the type 2 inflammatory cascade, which may explain why exacerbations are only partly abrogated. For example, type 2 airway inflammation results from several inflammatory signals in addition to IL-5. Clinically, this can be observed in how fractional exhaled nitric oxide (F eNO), which is driven by IL-13, may remain unchanged during anti-IL-5 treatment despite reduction in eosinophils, and how eosinophils may remain unchanged during anti-IL-4Rα treatment despite reduction in F eNO The broad inflammatory response involving cytokines including IL-4, IL-5 and IL-13 that ultimately results in the classic features of exacerbations (eosinophilic inflammation, mucus production and bronchospasm) is initiated by release of "alarmins" thymic stromal lymphopoietin (TSLP), IL-33 and IL-25 from the airway epithelium in response to triggers. The central, upstream role of these epithelial cytokines has identified them as strong potential therapeutic targets to prevent exacerbations and improve lung function in patients with type 2-high and type 2-low asthma. This article describes the effects of alarmins and discusses the potential role of anti-alarmins in the context of existing biologics. Clinical phenotypes of patients who may benefit from these treatments are also discussed, including how biomarkers may help identify potential responders.
引用
- Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020. PMID: 32586879. doi:10.1183/13993003.00260-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。